Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
CIBMTR analysis of infections w/in 100 days of ide-cel finds baseline infxn hx, KPS<80, grade≥2 CRS, grade≥3 neurotoxicity are independent predictors; infxn can result in inferior outcomes (2nd leading cause of death).”
Title: Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR Analysis
Authors: Kitsada Wudhikarn, Lohith Gowda, Qiran Ye, Temitope Oloyede, Michael Martens, Rahul Banerjee, Srinivas Devarakonda, Hongtao Liu, Megan Herr, Jo-Anne Young, Tania Jain, Ajoy Dias, Taiga Nishihori, Abu-Sayeef Mirza, Siddhartha Ganguly, Amer Beitinjaneh, Mahmoud Aljurf, Baldeep Wirk, Nosha Farhadfar, Yvonne Efebera, Miguel-Angel Perales, Christen Ebens, Hemant Murthy, Joshua Hill, Christopher Dandoy, Sanghee Hong, Zeinab El Boghdadly, Othman Salim Akhtar, Jeffery Auletta, Anna Huppler, Muhammad Bilal Abid
You can read the Full Article on Transplantation and Cellular Therapy.
You can find other articles featuring Robert Orlowski on OncoDaily.
